Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICEBOAT trial of oral fecal microbiota transplantation capsules versus placebo for severe irritable bowel syndrome
2019-003433-41Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2023
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing FMT capsule arm with Sham/placebo capsule arm (2 arms). Primary endpoint: IBS severity response at 12 weeks. Started Jan 2023; status: active.
02
Drugs
fecal microbiome transplant
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2019-003433-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003433-41.